Shares of Eli Lilly finished Thursday 3% higher despite an earnings report that showed sales of its blockbuster GLP-1 ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

Eli Lilly & Co.’s full-year earnings forecast came in line with analysts’ estimates as the company works to fix inventory problems with its new blockbuster obesity and diabetes drugs that weighed on ...

The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.

It turns out that the anti-obesity space isn't growing as fast as Eli Lilly or analysts anticipated, resulting in ...

Stock Market Today: Wall Street Mostly Rises After Encouraging Inflation Data Despite Lilly's Drag NEW YORK (AP) — Most U.S. stocks rose Tuesday following an encouraging update on inflation ...

Eli Lilly's Q4 FY24 guidance adjustment is due ... There are also some specific challenges related to the implementation of the Inflation Reduction Act (IRA) which come from the requirement ...

NEW YORK — Most U.S. stocks rose Tuesday following an encouraging update on inflation, though drops for Eli Lilly and other influential stocks kept indexes in check. The Standard & Poor’s 500 ...

New York – Most U.S. stocks rose Tuesday following an encouraging update on inflation, though drops for Eli Lilly and other influential stocks kept indexes in check. The S&P 500 rose 0.1% as ...